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Abstract
Background Treatment for metastatic colorectal cancer patients beyond the second line remains
challenging, highlighting the need for early phase trials of combination therapies for patients who
had disease progression during or following two prior lines of therapy. Leveraging hybrid control
design in these trials may preserve the beneﬁts of randomization while strengthening evidence by
integrating historical trial data. Few examples have been established to assess the applicability of
such design in supporting early phase metastatic colorectal cancer trials.
Methods MORPHEUS-CRC is an umbrella, multicenter, open-label, phase Ib/II, randomized,
controlled trial (NCT03555149), with active experimental arms ongoing. Patients enrolled
were assigned to a control arm (regorafenib, 15 patients randomized and 13 analysed) or
multiple experimental arms for immunotherapy-based treatment combinations. One
experimental arm (atezolizumab + isatuximab, 15 patients randomized and analysed) was
completed and included in the hybrid-control study, where the hybrid-control arm was
constructed by integrating data from the IMblaze370 phase 3 trial (NCT02788279). To
estimate treatment efﬁcacy, Cox and logistic regression models were used in a frequentist
framework with standardized mortality ratio weighting or in a Bayesian framework with
commensurate priors. The primary endpoint is objective response rate, while disease control
rate, progression-free survival, and overall survival were the outcomes assessed in the
hybrid-control study.
Results The experimental arm showed no efﬁcacy signal, yet a well-tolerated safety proﬁle in
the MORPHEUS-CRC trial. Treatment effects estimated in hybrid control design were
comparable to those in the MORPHEUS-CRC trial using either frequentist or Bayesian
models.
Conclusions Hybrid control provides comparable treatment-effect estimates with generally
improved precision, and thus can be of value to inform early-phase clinical development in
metastatic colorectal cancer.

Plain language summary
Treatment of patients with metastatic
colorectal cancer – meaning that it has
spread to other parts of the body – is
difﬁcult, and new therapies are needed for patients when standard
therapies stop working. We compare
a combination of drugs with a standard treatment for patients with
metastatic colorectal cancer in a clinical trial, in which patients are randomly allocated to either the
combination or the control (standard)
treatment. We ﬁnd that while the
combination is safe, it isn’t effective.
We also show, however, that we can
combine data from our control group
and the control group of a previous
trial to more precisely estimate treatment effects. Statistical approaches
such as this to combine data from
trials may mean that fewer patients
have to be recruited to control groups
in future trials, to improve access to
potentially effective new treatments.
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andomized controlled trials are regarded as the gold standard for evaluating effectiveness of treatments, yet regulatory agencies are becoming more receptive to
supplementing or replacing a control arm with historical data
from previously completed trials, especially in rare and pediatric
diseases or for life-threatening cancer indications with few
treatment options1,2. In such scenarios, randomizing patients to
control arms may be less acceptable due to ethical or feasibility
considerations, leading to a higher proportion of patients dropping out when randomized to control arms or less likely to
consent if there are higher odds of being randomized to control
arms3. Moreover, even in trials of more-prevalent diseases or with
speciﬁc eligibility criteria, challenges may be found during patient
recruitment—for instance, in late-stage cancer trials with
requirements for speciﬁc biomarker status4. Hybrid-control
design using relevant individual patient data from historical
clinical trials is being explored as a way to achieve more patientcentric, cost-effective, and accelerated clinical development, since
fewer patients are needed for standard-of-care or placebo-control
arms5,6. How to determine the amount of borrowing for the
control arm is based on comparability between historical- and
concurrent-control arms, a key question for implementing a
hybrid-control design7, and few examples have been established
to assess the applicability of such design in supporting early-trial
development.
Treatment for metastatic colorectal cancer (mCRC) patients
beyond the second line remains challenging, despite the success of
single-agent checkpoint inhibition in the patient population with
microsatellite instability-high status. mCRC patients are mostly
microsatellite stable, and thus do not respond to the single-agent
checkpoint inhibition, highlighting the need for combination
therapies. The MORPHEUS platform consists of multiple randomized umbrella phase 1b/2 trials designed to identify early
efﬁcacy signals in small cohorts and accelerate development of
treatment combinations across a wide scope of cancer
indications8. In the MORPHEUS mCRC trial, patients with
microsatellite stable tumors who had been refractory to the ﬁrst
and second line of therapies were randomized to either experimental arms or a control arm with regorafenib, a standard-ofcare therapy in this disease setting. The relatively small sample
size inherent to early-phase trials can limit their potential to
detect a treatment effect. Here we report the primary results of
the experimental arm (atezolizumab + isatuximab) and the control arm (regorafenib) and investigate the hybrid control trial
design with data integrated from historical control arm data of
the IMblaze370 trial. The combination of atezolizumab plus isatuximab lacks efﬁcacy, while the safety proﬁle of the experimental
arm is consistent with that of the control arm. The use of hybrid
control design improves precision while maintains accuracy of
estimates from a randomized trial.
Methods
Study design. This study established a hybrid-control arm for the
MORPHEUS-CRC trial using historical control data from the
IMblaze370 trial. MORPHEUS-CRC (ClinicalTrials.gov Identiﬁer: NCT03555149) is an ongoing, phase 1b/2, open-label, multicenter, randomized study designed to identify early signals of
safety and efﬁcacy of immunotherapy-based treatment combinations in patients with refractory microsatellite-stable mCRC8,9.
Patients in the MORPHEUS-CRC trial were randomly assigned
to different treatment arms with a permuted-block randomization
method; study sites obtained patients’ identiﬁcation numbers and
treatment assignments from an interactive voice or web-based
response system (IxRS). The control arm (regorafenib) and the
experimental arm (atezolizumab + isatuximab) were included in
2

this study and were enrolled between September 2018 and August
2019 (Supplementary Fig. 1). IMblaze370 (ClinicalTrials.gov
Identiﬁer: NCT02788279) is a completed, phase 3, multicenter,
open-label, randomized trial study that enrolled patients with
mCRC who had disease progression with at least 2 previous
systemic chemotherapy regimens between July 2016 and January
201710. Patients in the IMblaze370 control arm who met the
MORPHEUS-CRC eligibility criteria were selected to build an
external-control arm (Supplementary Note 2). A detailed comparison of eligibility criteria in the IMblaze370 and MORPHEUSCRC trials is in Supplementary Data File 1. The external-control
arm was incorporated into the MORPHEUS-CRC concurrentcontrol arm to construct a hybrid-control arm using a frequentist
model with propensity score (PS) weighting or a Bayesian
dynamic borrowing method. An overview of the study design is
shown in Fig. 1. MORPHEUS-CRC trial was reviewed by the
institutional review board at each site (Supplementary Note 4), as
well as the IMblaze370 trial10. All participants provided informed
written consent. The present hybrid-control study was not prespeciﬁed in the MORPHEUS-CRC trial protocol. The study followed the Consolidated Standards of Reporting Trials
(CONSORT) reporting guideline (Supplementary Fig. 3).
Outcome assessment. Investigator-assessed objective response
rate (ORR) was the primary endpoint for MORPHEUS-CRC. For
hybrid control analyses, the key secondary endpoints of disease
control rate (DCR), investigator-assessed progression-free survival (PFS), and overall survival (OS) were the outcomes evaluated.
ORR was not evaluated in the hybrid control analyses, because no
response was observed in either of the arms. DCR was deﬁned as
the proportion of patients with complete or partial response at
any time during the trial or stable disease for at least 12 weeks in
the MORPHEUS-CRC. Similar deﬁnition of DCR was applied in
the IMblaze370 trial, but with stable disease for at least 16 weeks.
As the time interval for response assessment was every 6 weeks in
the MORPHEUS-CRC and every 8 weeks in the IMblaze370 trial,
the DCR in the IMblaze370 trial at 12 weeks was inferred using
tumor overall response assessment at 8 and 16 weeks. Speciﬁcally,
if a patient showed progressive disease at 8 weeks in the
IMblaze370 trial, then the response for that patient at 12 weeks
was deﬁned as progressive disease; if a patient showed stable
disease at both 8 and 16 weeks, then the response for that patient
at 12 weeks was deﬁned as stable disease; otherwise, a patient’s
response was set as unknown. Disease progression was determined by clinical investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.111. PFS was
deﬁned as the time from trial randomization to the occurrence of
disease progression or death (whichever occurs ﬁrst) or end of
trial follow-up. OS was deﬁned as the time from trial randomization to the occurrence of death or end-of-trial follow-up. PFS
and OS time in the external-control arm were truncated to match
with the maximum PFS and OS time of the MORPHEUS-CRC
trial, respectively. Safety was also reported for the MORPHEUSCRC using the National Cancer Institute’s The Common Terminology Criteria for Adverse Events, version 4.0.
Propensity score estimation. Potential imbalance of predeﬁned
baseline characteristic and prognostic factors (hereafter referred
to as baseline covariates) between the MORPHEUS experimental
arm and the external-control arm were adjusted using PS with
standardized mortality ratio weighting (SMRW) method. The
SMRW method was preferred to the inverse probability of
treatment weighting (IPTW) method in this scenario, due to
considerations given in the Supplementary Note 1. PS was estimated using a multivariate logistic regression model adjusted for
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Hybrid control construction
Frequentist model with propensity score weighting
Bayesian dynamic borrowing

Treatment efficacy
estimation
(DCR, PFS and OS)

Atezolizumab + isatuximab (n = 15)

MORPHEUS-CRC
18-week interim data release
(March 2020)

R
Regorafenib (n = 13)

Regorafenib (n = 28)

IMblaze370 control arm

Propensity score weighting
To balance prognostic and
confounding factors between arms

External control build
Applied MORPHEUS-CRC
eligibility criteria

Fig. 1 Study overview. Patients from the IMblaze370 trial control arm (regorafenib) who received regorafenib as the third-line treatment and met the
MORPHEUS-CRC trial eligibility criteria were selected for the external-control cohort and incorporated in the MORPHEUS concurrent control arm to
construct a hybrid-control cohort. DCR disease control rate, EC external control, HC hybrid control, I/E inclusion/exclusion, mCRC metastatic colorectal
cancer, OS overall survival, PFS progression-free survival, PS propensity score, R randomization.

predeﬁned covariates. This model assumed a linear relationship
between each baseline covariate and the log-odds of the group
assignment (being in the MORPHEUS-CRC experimental arm vs
external-control arm). PS was calculated for each patient, representing a patient’s probability of being in the MORPHEUS-CRC
experimental arm, conditioning on all baseline covariates.
The baseline covariates selected included age, sex, presence of
liver metastasis, time from metastatic diagnosis to baseline (> vs
≤18 months), and Eastern Cooperative Oncology Group (ECOG)
performance score (0 vs 1). Covariate selection was based on data
availability, model convergence, and potential clinical importance
with respect to their prognostic impact in the metastatic
refractory setting12. Balance was assessed with standardized mean
difference (SMD), where covariates with SMD < 0.25 were
deemed as sufﬁciently balanced13,14.
Hybrid-control modeling
Bayesian borrowing. Combining randomized- and historicalcontrol arms in a Bayesian framework allows a dynamic proportion of the historical-control arm to be used in the hybridcontrol arm in a data-driven manner. The proportion was
determined by commensurability between the external-control
and the concurrent-control arm. This was derived ﬁrstly based on
one’s subjective determination via the prior setting on a value for
the variance of difference between mean treatment-effect sizes of
the two control arms, then updated with data likelihood, to
produce a posterior belief for the proportion of borrowing7. A
prior setting for the variance incorporates one’s initial guidance
for the degree of borrowing; by increasing values of the prior, one
places more emphasis on the randomized control and less on the
historical control, i.e., discouraging the borrowing, and vice versa.
For the DCR analyses, given there were only two levels
observed, stable disease (SD) and progressive disease (PD), we
assumed DCR for a patient i (yi) to follow a Bernoulli distribution
yi ~ Bernoulli(pi), with pi referring to the probability of SD for the
patient i. We deﬁned γ0, γ1, and γ2 to be the logit function of pi
in the MORPHEUS-CRC experimental arm, the concurrentcontrol arm, and the external-control arm, respectively; γ1
follows a normal distribution with a mean of γ2 and a variance
of 1/τ, where τ follows a gamma(1,1) distribution; γ0 and γ1 are
both non-informative vague priors with the Gaussian normal
distribution.

For the PFS and OS analyses, we assumed survival time for a
patient i (ti) to follow a Weibull distribution ti ~ Weibull(r, μi), with
a shape of r ~ exp(10), and a scale parameter of μi. By setting the
natural logarithm of hazards to be β0, β1, and β2 in the
MORPHEUS-CRC experimental arm, the concurrent-control
arm, and the external-control arm, respectively, we derived μi = eβ0,
eβ1, eβ2 in each corresponding arm; β1 follows a normal distribution
with a mean of β2 and a variance of 1/τ, where τ parametrizes
commensurability and determines the degree of borrowing, which
follows a half-Cauchy (0, 25) distribution; β0 and β1 are set to be
noninformative, following standard normal distributions15.
When evidence for commensurability is weak, τ is forced toward
zero, increasing the prior variance of β1 by 1/τ, thereby
discouraging borrowing from external data5. To assess the potential
impact of the prior choices of τ on the results, we performed
sensitivity analyses with different τ distributions. For the PFS and
OS, results were consistent across different prior distributions; for
the DCR, results changed slightly with priors (1/τ) of larger
variances, partially due to the very small sample size and thus very
large standard deviations of the result estimates (Supplementary
Table 1). Moreover, we assessed the amount of prior-data conﬂict
by visualising prior and posterior distributions of β coefﬁcients for
all three outcomes (Supplementary Fig. 2).
The implementation was written in JAGS16 using Markov chain
Monte Carlo with 3 parallel chains, each run for a 1000-iteration
burn-in period followed by a 20,000-iteration production run.
Frequentist with SMRW. Logistic regression was implemented for
the binary endpoint of DCR; Cox proportional hazards models
were implemented for the time-to-event endpoints, PFS and OS;
each model contained only one exposure variable, the group of
treatment (experimental vs control treatment), and was weighted
with SMRW to balance baseline covariates through the PS
method. Robust variance estimator was applied for weighted
models to account of within-subject correlations in the weighted
pseudo-population, because a lack of independence between
subjects can cause a naive model‐based variance estimator more
likely to be biased, and such robust method has been shown to be
an option for unbiased variance estimation in this setting17.
Statistical analysis. Baseline demographic and clinical characteristics were summarized in the external-control (regorafenib)
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arm derived from the IMblaze370 trial, and the MORPHEUSCRC concurrent-control (regorafenib) and experimental (atezolizumab + isatuximab) arms, separately. Experimental treatment
efﬁcacies were estimated by comparing the MORPHEUS-CRC
experimental arm to the concurrent-control or the hybrid-control
arm in a frequentist or a Bayesian framework. Survival time (PFS
and OS) was determined using the Kaplan–Meier estimator with
SMRW, with median point estimates and corresponding 95% CIs
summarized for each arm along with the Kaplan–Meier curves.
All analyses were conducted using RStudio version 1.3.0 and R
version 3.6.3.
Reporting summary. Further information on research design is
available in the Nature Research Reporting Summary linked to
this article.
Results
Primary MORPHEUS-CRC results. No responses occurred in
either the experimental arm–atezolizumab + isatuximab
(n = 15) or the control arm–regorafenib (n = 13) in the
MORPHEUS-CRC trial. DCR was 13.3% in the experimental
arm and 15.4% in the control arm. Median PFS was 1.4 months
(95% CI: 1.4–1.8) in the experimental arm and 2.8 months (95%
CI: 1.6–3.1) in the control arm; median OS was 5.1 months
(95% CI: 3.1–7.8) and 10.2 months (95% CI: 4.8, not reached
estimable) in the experimental and the control arms, respectively (Table 1). A summary of the safety data can be found in
Supplementary Tables 2–3. Overall, the atezolizumab +
isatuximab combination was well tolerated, with a manageable
safety proﬁle. The routine laboratory measurements at and post
baseline were comparable and, for both arms, mostly normal or
of the minimum grade of severity according to The Common
Terminology Criteria for Adverse Events. No new safety signals
were observed.
Study population. The external-control cohort was derived from
the IMblaze370 control arm who received regorafenib (n = 90).
Cohort attrition using the MORPHEUS-CRC eligibility criteria
(Supplementary Note 2) as ﬁltering steps yielded 28 patients who
constituted the external-control group (Fig. 2). There was no
major imbalance in the baseline demographic or clinical characteristics, including age, sex, race, time from metastatic diagnosis
to baseline, ECOG performance score, Rat Sarcoma (RAS) protooncogene mutational status, and presence of liver metastases
(Table 2). Regarding the region, the external-control patients
were mainly from Europe, whereas the MORPHEUS-CRC
patients were from North America, Asia, or Australia.
Balance of confounding variables. To account for potential
differences between the predeﬁned baseline covariates in the two
trials, we leveraged the PS approach, which is commonly used for
causal inference on treatment effects in observational studies18 or
single-arm trials supplemented with external-control design19–21.
Using this method, the external-control cohort was further
balanced on a selected subset of baseline variables, including age,
sex, time from metastatic diagnosis to baseline, ECOG performance score, and presence of liver metastases, with each variable
demonstrating an acceptable balance with SMD < 0.25 (Supplementary Fig. 4).
Efﬁcacy assessment. Three endpoints were used for treatment
efﬁcacy assessment: DCR, PFS, and OS. Five patients with
unknown response assessment were excluded from the external
dataset in the DCR analyses (Supplementary Table 4).
4

Table 1 MORPHEUS-CRC Treatment Efﬁcacy.
Atezolizumab + isatuximab Regorafenib
Conﬁrmed ORR, No. (%)
% [95% CI]a
SD, No. (%)
% [95% CI]b
PD, No. (%)
% [95% CI]b,c
DCR, No. (%)
% [95% CI]d
PFS, median survival
(months, 95% CI)a
OS, median survival
(months, 95% CI)a

(n = 15)

(n = 13)

0 (0.0)
[0, 21.8]
3 (20.0)
[4.3, 48.1]
10 (66.7)
[38.4, 88.2]
2 (13.3)
[1.7, 40.0]
1.4 (1.4–1.8)

0 (0.0)
[0, 24.7]
8 (61.5)
[31.6, 86.1]
3 (23.1)
[5.0, 53.8]
2 (15.4)
[1.9, 45.5]
2.8 (1.6–3.1)

5.1 (3.1–7.8)

10.2 (4.8-NE)

Clinical cutoff: 3 March 2020. No. number of patients, DCR disease control rate, NE not
estimable, ORR objective response rate, OS overall survival, PD progressive disease, PFS
progression-free survival, RECIST Response Evaluation Criteria in Solid Tumors, SD stable
disease, CI conﬁdence interval.
aPer INV RECIST 1.1.
bPatients were classiﬁed as achieving stable disease or progressive disease if assessment was at
least 6 weeks from randomization.
cOne patient treated with atezolizumab + isatuximab beyond progression had prolonged
disease stabilization.
dCriteria for disease control is either response and/or stable disease for at least 12 weeks.

In the original MORPHEUS-CRC trial, these three endpoints
favored the regorafenib arm, although the differences were not
statistically signiﬁcant. Using the hybrid control design in a
frequentist framework showed comparable estimates, with
substantial improvements in precision for all three endpoints
(Fig. 3).
Hybrid-control design with a Bayesian framework also showed
comparable estimates for all three endpoints. Precisions were
improved for the PFS and the OS, but not the DCR, indicating a
higher degree of commensurability between the 2 control arms
for the PFS and the OS (HR [95% CI] = 1.04 [0.67–1.63],
τmean = 3.52 × 105; HR [95% CI] = 1.00 [0.66–1.38], τmean = 7.48 ×
105 for the PFS and the OS, respectively, comparing hybrid-control
with concurrent-control arms, Supplementary Fig. 5), leading to an
effective borrowing of power. This was not the case for the DCR, as
the amount of borrowing was restricted due to a larger amount of
dissimilarity between the two control arms (OR [95% CI] = 0.83
[0.20–1.97], τmean = 13.15, comparing the hybrid control with the
concurrent-control arms, Supplementary Table 1).
Discussion
In this study, we constructed a hybrid-control arm using the
historical trial (IMblaze370) data to supplement a concurrent
randomized controlled trial (MORPHEUS-CRC) on treatment
efﬁcacy estimation based on three endpoints (DCR, PFS, and OS).
Comparison using the hybrid-control or the concurrent-control
arm led to similar experimental treatment-effect estimates across
the endpoints assessed, with the hybrid-control design generally
achieving greater precisions.
The degree of borrowing from the external-control cohort
depends on the similarity between the external-control and the
concurrent-control arm, and assessment of the similarity and
adjusting accordingly differentiates hybrid-control methods22. For
example, novel methods that use power priors23 or meta-analytic
predictive priors24 with PS-based selection of patients can assess
various degrees of between-trial heterogeneity, and adaptively
adjusting the amount of borrowing of external information. Here
we leveraged two methods: the ﬁrst was the static borrowing
method under the frequentist paradigm, and the second was the
dynamic borrowing method within the Bayesian framework. For
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90 (100%)

All regorafenib patients from IMblaze370
Including patients with 3L regorafenib only

42 (47%)
40 (44%)

Excluding patients with MSI-H
Excluding patients with BRAF mutations

38 (42%)

Excluding patients who have not received anti-angiogenic
or anti-EGFR therapies prior to the 3L therapy

31 (34%)

Excluding patients receiving corticosteroids
for brain metastases
Excluding patients with cerebrovascular accidents
within 3 months prior to the 3L therapy
Excluding patients who have not received treatments with
5FU, oxalipatin, or irinotecan prior to the 3L therapy

31 (34%)
31 (34%)
28 (31%)
0

25

50

75

No. of patients

Fig. 2 IMBlaze370 control cohort attrition. The external-control cohort was built with the MORPHEUS trial eligibility criteria applied in the IMBlaze370
control cohort. 3 L third-line, 5FU ﬂuorouracil, BRAF B-Raf proto-oncogene, serine/threonine kinase, EGFR epidermal growth factor receptor, MSI-H
microsatellite instability–high.

Table 2 Comparison of the Baseline Demographic and Disease Characteristics Between the External-Control Arm Derived From
the IMblaze370 and the MORPHEUS-CRC Control and Experimental Arms.

Total Sample size
Age at baseline, mean (SD)
Sex, No. (%)
Female
Male
Race, No. (%)
White
Non-White
Unknown
Region, No. (%)
North America
Europe
Asia-Paciﬁc
Time from metastatic diagnosis to baseline,
No. (%)
<18 months
≥18 months
Unknown
ECOG, No. (%)
0
1
RAS, No. (%)
Wild type
Mutant
Unknown
Liver metastases, No. (%)
No
Yes

IMblaze370

MORPHEUS-CRC

Regorafenib (EC)
28
57.0 (9.6)

Atezo + Isa
15
52.2 (12.0)

Regorafenib
13
59.5 (10.5)

12 (42.9)
16 (57.1)

6 (40.0)
9 (60.0)

7 (53.8)
6 (46.2)

21 (84.0)
4 (16.0)
3

10 (71.4)
4 (28.6)
1

8 (66.7)
4 (33.3)
1

6 (21.4)
17 (60.7)
5 (17.9)

11 (73.3)
1 (6.7)
3 (20.0)

6 (46.2)
2 (15.4)
5 (38.5)

7 (25.0)
21 (75.0)
0

7 (46.7)
8 (53.3)
1

4 (30.8)
8 (61.5)
0

13 (46.4)
15 (53.6)

5 (33.3)
10 (66.7)

6 (46.2)
7 (53.8)

10 (38.5)
16 (61.5)
2

6 (40.0)
9 (60.0)
0

8 (61.5)
5 (38.5)
0

10 (35.7)
18 (64.3)

6 (40.0)
9 (60.0)

4 (30.8)
9 (69.2)

P value (EC vs Atezo + Isa)

SMD (EC vs Atezo + Isa)

0.178
0.859

0.445
0.058

0.362

0.306

0.002

1.498

0.161

0.464

0.417

0.27

0.924

0.032

0.786

0.088

Statistical differences between the external-control and the MORPHEUS experimental arm (atezolizumab + isatuximab) were assessed using (1) P values calculated via the 2-tailed χ2 (or Fisher exact)
test for all categorical variables or the Wilcoxon rank-sum test for the age variable, and (2) standardized mean difference.
Atezo atezolizumab, EC external control, ECOG Eastern Cooperative Oncology Group, Isa isatuximab, RAS Rat Sarcoma proto-oncogene.

the ﬁrst method, the external-control cohort was balanced for
baseline covariates using SMRW and a frequentist model
was subsequently applied for treatment-effect estimates. The
resultant weighted pseudo-cohort can be regarded as a statistically
balanced external-control arm that is able to merge with the
concurrent-control arm to form the hybrid-control arm. For the
second method, a commensurate prior was used to assess how
comparable the external-control arm was to the randomizedcontrol arm. The posterior distribution of the commensurate prior
is determined via a data-driven process, which further informs the
degree of borrowing. Each method has its pros and cons, as discussed below; we also compared each method in a simulation
framework with known parameters to reveal which method has
more desirable statistical properties (Supplementary Note 3).

In this study we observed that the frequentist approach with
SMRW was generally more effective for the precision improvement of treatment-effect estimates; however, it is more likely to be
biased owing to residual imbalance of a priori selection of confounding factors or unmeasured confounding. We adjusted for
ﬁve clinically relevant covariates, which were prioritized based on
their potential inﬂuence on prognosis in the metastatic CRC
refractory setting. Other factors with potential prognostic impact
on mCRC were not included due to data incompleteness, model
nonconvergence, or discrepancies of data collection or trial design
between the historical trial and the MORPHEUS-CRC trial.
Among the factors excluded were RAS mutation status and tumor
sidedness. Although these factors appear to be prognostic at the
time of diagnosis and initial treatment of mCRC25, their
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DCR
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0
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23

0.78 (0.13, 4.61)

Bayesian

CC

13

0

0.82 (0.18, 2.29)

Bayesian borrowing

HC

13

23

0.82 (0.19, 2.91)

IMblaze370
EC
(n = 23)

OR (95%CI)

0

2

4
OR (95% CI)

6

Favor comparator arm Favor experimental arm
B

PFS

No. of patients in comparator arm

Model

Comparator arm

MORPHEUS
CC
(n = 13)

Frequentist

CC

13

0

1.97 (0.88, 4.42)

Frequentist with SMRW

HC

13

28

1.91 (1.01, 3.58)

Bayesian

CC

13

0

1.90 (0.87, 3.63)

Bayesian borrowing

HC

13

28

2.10 (1.03, 3.74)

IMblaze370
EC
(n = 28)

HR (95%CI)

1

2

3
HR (95% CI)

4

Favor experimental arm Favor comparator arm
C

OS

No. of patients in comparator arm

Model

Comparator arm

MORPHEUS
CC
(n = 13)

Frequentist

CC

13

0

2.04 (0.75, 5.58)

Frequentist with SMRW

HC

13

28

1.47 (0.71, 3.08)

Bayesian

CC

13

0

1.91 (0.72, 4.22)

Bayesian borrowing

HC

13

28

1.88 (0.82, 3.60)

IMblaze370
EC
(n = 28)

HR (95%CI)

1

2

3
HR (95% CI)

4

5

Favor experimental arm Favor comparator arm

Fig. 3 Treatment-effect estimates derived from experimental arm vs concurrent control arm or hybrid control arm. Treatment efﬁcacy was assessed via
(A) DCR, (B) PFS, and (C) OS endpoints comparing the MORPHEUS experimental arm (atezolizumab + isatuximab) to the concurrent-control arm or the
hybrid-control arm (regorafenib), separately. CC concurrent control, DCR disease control rate, EC external control, HC hybrid control, HR hazard ratio, OR
odds ratio, OS overall survival, PFS progression-free survival, SMRW Standardized mortality ratio weighting.

prognostic effect in the refractory setting is unclear. Nonetheless,
the covariates taken into consideration for confounding adjustment may be insufﬁcient to achieve a complete balance between
the external- and the concurrent-control arms, leading to a
potential risk for bias that is inherited by the subsequent frequentist model-based experimental treatment-effect estimation.
The Bayesian dynamic borrowing, in contrast, can detect potential
dissimilarities and adapt the amount of borrowing based on estimation of the commensurability parameter. Therefore, if the externally derived and the concurrent control have similar endpoint
distributions, then a larger amount of the external control data is
incorporated, leading to a substantially narrowed credible set, and
vice versa. However, when the trial sample size is small, model
inferences are heavily sensitive to prior settings7. In our analyses, the
prior distributions for the treatment effects (i.e., beta coefﬁcients)
were set as standard normal distributions for all three endpoints. Due
to these relatively informative priors, the credible sets from the
Bayesian models were narrower than the conﬁdence intervals from
frequentist models in analyses with the concurrent control. Moreover,
we applied a weakly informative prior distribution on the commensurability parameter, which provided an advantage of borrowing
at a conservative level to reduce inﬂation of type 1 error rate, at a cost
of potentially over-attenuating the inﬂuence of historical control data
on the treatment-effect estimation26.
This study has several limitations. First, as with all early-phase
trials, there is a limitation owing to a small sample size. Therefore,
for causal inferences, PS models cannot handle a large number of
covariates, leading to potentially inadequate adjustment of confounders. In consideration of this, we applied a Bayesian method
independent of PS adjustment, which counteracts the limitations
6

suffered by the frequentist models with PS weighting. In turn, we
also used the frequentist model to benchmark the prior settings
for the Bayesian models. Second, despite similar trial populations
and randomization of the historical and current trials, the historical trial’s recruitment period was initiated ~2 years before the
MORPHEUS-CRC. These noncontemporary cohorts potentially
create heterogeneity between the external-control arm and the
concurrent trial. For example, during the two-year period since
the IMblaze370 trial initiation, optimization of regorafenib
dosing27 and improved toxicity management were able to be
incorporated in the MORPHEUS-CRC trial, which may have
translated into better outcomes in control patients in the
MORPHEUS-CRC compared with those in the IMblaze370. This
potential source of heterogeneity may not be fully addressed,
although by design, any unknown differences between the two
trials have been embedded in the Bayesian commensurability
prior setting. Third, deﬁnitions of the clinical outcomes vary in
terms of response assessment frequencies (6 vs 8 weeks), which
has led to missing DCR values in the external-control cohort,
whereas, for the PFS and the OS, such differences in the frequencies of outcome assessment exerted minimal effects because
cumulative survival probability distributions between the
external-control and the concurrent-control cohorts were comparable, especially after balancing the baseline covariates.
In conclusion, this proof-of-concept study shows that a hybridcontrol design using historical trial data from the IMblaze370
recapitulates the results obtained with the randomized-control
arm of the MORPHEUS-CRC trial, with generally greater precisions. This result suggests that hybrid-control design may be used
in early phase trials to support more conﬁdent decision-making
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to inform later-phase development. This study also demonstrates
the feasibility of supplementing a concurrent-control arm with a
completed clinical trial–derived external-control arm. Overall, the
hybrid-control design has the potential to increase overall trial
attractiveness by favoring randomization to potentially transformative experimental arms. This approach may inform and
accelerate early-phase clinical development, although it is not a
shortcut to an approval of clinical practice during the process of
drug development. Further research is warranted to expand this
work in the refractory mCRC setting as well as other cancer
indications.
Data availability
Qualiﬁed researchers engaged in rigorous, independent scientiﬁc research may request
access to individual patient-level data upon request through https://www.roche.com/
innovation/process/clinical-trials/data-sharing/request. Data from individual patients can
be requested 18 months after relevant clinical studies being approved by the regulatory
authorities or will not be developed further. Requests outside this scope will be
considered on a case-by-case basis through enquiries via the https://vivli.org site. Further
details on data sharing and how to request access to related clinical study documents are
available at https://www.roche.com/innovation/process/clinical-trials/data-sharing/.
Information on the clinical trials can be found on clinicaltrials.gov. The IMblaze370 trial
is published10.

Code availability
Custom code for Bayesian dynamic borrowing is accessible at https://doi.org/10.5281/
zenodo.651462928. Code for other analyses, including external cohort attrition and
propensity score analyses, is available upon request from the author via https://github.
roche.com/PHC/PHC-619/.
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